Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034930 | 0.92 | PTK2 (0.38) | MAPK14MAPK8PTK2CDK4CCNA2 | |
| SCHEMBL15041835 | 0.84 | PTK2 (0.42) | MAPK14MAPK8PTK2CDK4 | |
| SCHEMBL15041396 | 0.83 | MAPK14 (0.40) | MAPK14MAPK8PTK2 | |
| SCHEMBL15041361 | 0.83 | MAPK14 (0.38) | MAPK14MAPK8PTK2CDK4CCNA2 | |
| SCHEMBL15041413 | 0.80 | MAPK14 (0.39) | MAPK14MAPK8PTK2CDK4CCNA2 | |
| SCHEMBL15041376 | 0.78 | MAPK14 (0.36) | MAPK14MAPK8PTK2CDK4CCNA2 | |
| SCHEMBL15041774 | 0.78 | MAPK14 (0.41) | MAPK14MAPK8CDK4CCNA2CCND1 | |
| SCHEMBL15041629 | 0.78 | MAPK14 (0.38) | MAPK14MAPK8CDK4 | |
| SCHEMBL15035811 | 0.77 | PTK2 (0.41) | MAPK14MAPK8PTK2CDK4CCNA2 | |
| SCHEMBL15034788 | 0.77 | CDK4 (0.46) | PTK2CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | MAPK14 139/4885MAPK8 14/4885PTK2 74/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | MAPK14 382/4885MAPK8 493/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.